Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial

Autor: Kersten, Marie José, Dreyling, Martin, Linton, Kim M. ^*, Chitu, Dana ^*, Tonino, Sanne ^*, Kap, Marcel ^*, Liu, Roberto D ^*, Chamuleau, Martine E.D., Visser, Hein P.J. ^*, De Jongh, Eva ^*, Marijt, Erik WAF, Leijs, Maria B.L. ^*, Bilgin, Yavuz M. ^*, Dürig, Jan ^*, McKay, Pamela ^*, Snijders, Tjeerd J.F. ^*, Pettitt, Andrew ^*, Minnema, Monique C., Prange-Krex, Gabriele ^*, Cuijpers, Maria ^*, Böhmer, Lara H. ^*, Tick, Lidwine W., Florschütz, Axel ^*, Silbermann, Matthijs ^*, Fijnheer, Rob ^*, Beeker, Aart, Tolboom, Nelleke ^*, Mitea, Cristina ^*, Arens, Anne IJ ^*, Zwezerijnen, Gerben JC ^*, Klapper, Wolfram ^*, Coupland, Sarah E. ^*, de Jong, Daphne ^*, Doorduijn, Jeanette K., Zijlstra, Josée M.

Publikováno v: In Blood 15 November 2022 140 Supplement 1:2283-2285

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus phaselenalidomide:II HOVON trial results of a multicenter

Autor: Chamuleau, Martine E.D., Burggraaff, Coreline N., Nijland, Marcel, Bakunina, Katerina, Mous, Rogier, Lugtenburg, Pieternella J., Dierickx, Daan, van Imhoff, Gustaaf W., Vermaat, Joost S.P., Marijt, Eric A.F., Visser, Otto, Mandigers, Caroline, Bilgin, Yavuz M., Beeker, Aart, Durian, Mark F., van Rees, Bas P., Bohmer, Lara H., Tick, Lidwine W., Boersma, Rinske S., Snijders, Tjeerd J.F., Schouten, Harry C., Koene, Harry R., de Jongh, Eva, Hijmering, Nathalie, Diepstra, Arjan, van de Berg, Anke, Arens, Anne I.J., Huijbregts, Julia, Hoekstra, Otto, Zijlstra, Josee M., de Jong, Daphne, Kersten, Marie José

Publikováno v: Chamuleau, M E D, Burggraaff, C N, Nijland, M, Bakunina, K, Mous, R, Lugtenburg, P J, Dierickx, D, van Imhoff, G W, Vermaat, J S P, Marijt, E A F, Visser, O, Mandigers, C, Bilgin, Y M, Beeker, A, Durian, M F, van Rees, B P, Bohmer, L H, Tick, L W, Boersma, R S, Snijders, T J F, Schouten, H C, Koene, H R, de Jongh, E, Hijmering, N, Diepstra, A, van de Berg, A, Arens, A I J, Huijbregts, J, Hoekstra, O, Zijlstra, J M, de Jong, D & Kersten, M J 2020, ' Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus phase lenalidomide : II HOVON trial results of a multicenter ', Haematologica, vol. 105, no. 12, pp. 2805-2812 . https://doi.org/10.3324/haematol.2019.238162

atients with MYC-rearrangement positive large B-cell lymphoma (MYC+ LBCL) have an inferior prognosis following standard first-line therapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) compared to patients with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_____10172::5af8bf5ff7b52d148203bf25d917bb33
https://research.vumc.nl/en/publications/9c281431-14b3-4c52-b204-2c3b54a430c0